NCT00620685View on ClinicalTrials.gov

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Placebo

Tablet, once daily for 4 weeks

DRUG

PH-797804

Tablet, 1 mg PH-797804, once daily for 4 weeks

DRUG

PH-797804

Tablet, 5 mg PH-797804, once daily for 4 weeks

Trial Locations (7)

16635

Pfizer Investigational Site, Duncansville

21702

Pfizer Investigational Site, Frederick

33169

Pfizer Investigational Site, Miami

48025

Pfizer Investigational Site, Bingham Farms

49007

Pfizer Investigational Site, Kalamazoo

80909

Pfizer Investigational Site, Colorado Springs

85013

Pfizer Investigational Site, Phoenix

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00620685 - A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate | Biotech Hunter | Biotech Hunter